Pearl Huang

Pearl Huang

Company: Dunad Therapeutics

Job title: CEO


Panel Discussion: How do we Differentiate Degraders from Inhibitors as a Therapeutic Modality? 10:00 am

How do we break away from the inhibitor-based ligands like BRAF? Do we need to? How are we finding new, exciting targets? How do we address the problems with VHL pharmacology such as its larger size?Read more

day: Conference Day Two

A Hanson Wade Group Company

© Copyright 2024 Hanson Wade | Design and site by Event Engine | Hanson Wade Limited is registered in England & Wales, number 06752216.
Registered Office: Eastcastle House, 27/28 Eastcastle Street, London, W1W 8DH.